The financials
Arcus Biosciences, Inc. by the numbers
Arcus Biosciences, Inc. (RCUS) reported revenue of $41M in Q2 2026 (quarter ended June 30, 2026), down 74% from the same quarter a year earlier. That came with net loss of $91M. For the full year FY2025, revenue was $247M (−4.3% year on year) and net income −$353M. Its largest product in 2026-Q2 was Access Rights at $21M, 57% of the disclosed total, just ahead of License And Development Services at 22%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $41M | $160M | −74% |
| Operating income | −$96M | −$8.0M | n/a |
| Net income | −$91M | $0 | n/a |
| Diluted EPS | −$0.72 | $0.00 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Access Rights | $21M | 57% |
| License And Development Services | $8.0M | 22% |
| License | $4.0M | 11% |
| RD Services | $4.0M | 11% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $37.0M (+118%)
Access Rights grew +250% year on yearLicense And Development Services -95% year on year
Segment Latestquarter on quarteryear on year
- Access Rights$21.0M$21.0MQoQ +600%year on year +250%+600%+250%
- License And Development Services$8.0M$8.0MQoQ -20%year on year -95%-20%-95%
- License$4.0M$4.0MQoQ -year on year ---
- RD Services$4.0M$4.0MQoQ +100%year on year +100%+100%+100%
- License And Development Services--QoQ -year on year ---
- License And RD Services--QoQ -year on year ---
- Other Services$0.00$0.00QoQ -100%year on year --100%-